Literature DB >> 16093591

Frequency of gouty arthritis in patients with end-stage renal disease in Japan.

Iwao Ohno1, Kimiyoshi Ichida, Hideaki Okabe, Miho Hikita, Daijiro Uetake, Hiroaki Kimura, Hajime Saikawa, Tatsuo Hosoya.   

Abstract

OBJECTIVE: The purpose of this study was to investigate gouty arthritis in Japanese patients with end-stage renal disease (ESRD).
METHODS: Questionnaires plus patient interviews and reviews of medical records were used to investigate gouty arthritis in 493 Japanese patients with ESRD receiving maintenance dialysis.
RESULTS: The frequency of gouty arthritis was 4.1% for female patients and 15.4% for male patients greater than 2 years before the start of dialysis, and 0.6% for female patients and 7.7% for male patients less than 2 years before the start of dialysis. After the start of dialysis the frequency was 3.4% for the first 2 years and 1.2% thereafter in male patients, but no gouty arthritis appeared in female patients. Although the annual number of gouty attacks was 2.0+/-4.2 greater than 2 years before the start of dialysis, and 1.9+/-6.6 less than 2 years before the start of dialysis, the annual number of attacks decreased significantly after the start of dialysis to 0.2+/-0.7 in the first 2 years and 0.1+/-0.6 thereafter.
CONCLUSIONS: The frequency of gouty arthritis in Japanese patients with ESRD is similar to that of patients with hyperuricemia in the general population and it is decreased slightly before dialysis; however, the frequency decreases markedly after dialysis.

Entities:  

Mesh:

Year:  2005        PMID: 16093591     DOI: 10.2169/internalmedicine.44.706

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  The 3-Year Incidence of Gout in Elderly Patients with CKD.

Authors:  Vivian S Tan; Amit X Garg; Eric McArthur; Ngan N Lam; Manish M Sood; Kyla L Naylor
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-02       Impact factor: 8.237

2.  Association of incident gout and mortality in dialysis patients.

Authors:  Scott D Cohen; Paul L Kimmel; Robert Neff; Lawrence Agodoa; Kevin C Abbott
Journal:  J Am Soc Nephrol       Date:  2008-05-28       Impact factor: 10.121

3.  Risk of end-stage renal disease associated with gout: a nationwide population study.

Authors:  Kuang-Hui Yu; Chang-Fu Kuo; Shue-Fen Luo; Lai-Chu See; I-Jun Chou; Hsiao-Chun Chang; Meng-Jiun Chiou
Journal:  Arthritis Res Ther       Date:  2012-04-18       Impact factor: 5.156

4.  Management of Gout and Hyperuricemia in CKD.

Authors:  Ana Beatriz Vargas-Santos; Tuhina Neogi
Journal:  Am J Kidney Dis       Date:  2017-04-26       Impact factor: 8.860

Review 5.  Impact of the COVID-19 pandemic on the management of patients with end-stage renal disease.

Authors:  Szu-Yuan Li; Yu-Shuo Tang; Yu-Jiun Chan; Der-Cherng Tarng
Journal:  J Chin Med Assoc       Date:  2020-07       Impact factor: 2.743

6.  Febuxostat for hyperuricemia in patients with advanced chronic kidney disease.

Authors:  Tetsu Akimoto; Yoshiyuki Morishita; Chiharu Ito; Osamu Iimura; Sadao Tsunematsu; Yuko Watanabe; Eiji Kusano; Daisuke Nagata
Journal:  Drug Target Insights       Date:  2014-08-13

7.  Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient.

Authors:  Lynda Ann Frassetto; Suzanne Gibson
Journal:  Case Rep Nephrol       Date:  2016-04-21

8.  Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack.

Authors:  Jung Sun Lee; Oh Chan Kwon; Ji Seon Oh; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo; Seokchan Hong
Journal:  Korean J Intern Med       Date:  2019-01-28       Impact factor: 2.884

Review 9.  Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.

Authors:  Lisa K Stamp; Hamish Farquhar; Huai Leng Pisaniello; Ana B Vargas-Santos; Mark Fisher; David B Mount; Hyon K Choi; Robert Terkeltaub; Catherine L Hill; Angelo L Gaffo
Journal:  Nat Rev Rheumatol       Date:  2021-07-30       Impact factor: 20.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.